Selenium and Polycystic Ovary Syndrome; Current Knowledge and Future Directions: A Systematic Review

Abstract

Polycystic ovary syndrome (PCOS), as the most common endocrine disorder in reproductive-aged women, is recognized by hyperandrogenism and insulin resistance. Selenium (Se) potentially possesses therapeutic effects on PCOS due to antioxidant and insulin-like properties. This systematic review evaluates the potential role of Se in the complications of PCOS. A systematic review was performed on published studies reporting the effects of Se on PCOS. Three major databases including PubMed, Scopus, and Google Scholar were searched until December 2018. A total of 7 human studies and two in vitro studies met the inclusion criteria. Two out of three case-control studies showed that serum Se levels tend to decrease in patients with PCOS. Of four studies that evaluated the impact of Se supplementation on insulin resistance, only one study showed protective effects of Se against insulin resistance. Two out of three studies reported the antioxidant effect of Se. Few studies investigating anti-androgenic effect of Se presented controversial results. There were three studies that evaluated the anti-hyperlipidemic effect of Se, of which two surveys indicated the lowering effects of Se on VLDL and LDL-cholesterol. The reviewed studies confirmed inverse relationships between serum Se levels and some androgenic hormones in PCOS. Se is able to attenuate insulin resistance and dyslipidemia. The available data are currently insufficient to support the protective effects of Se on PCOS.

Key words

selenium - PCOS - insulin resistance - dyslipidemia

• References

• 1 Shukla A, Mandel L. Polycystic Ovarian Syndrome. Obesity Management. Berlin: Springer; 2019: 31-40
• 2 Azziz R, Carmina E, Chen Z. et al. Polycystic ovary syndrome. Nat Rev Disease Primers 2016; 2: 16057
• 3 Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37: 467-520
• 4 Rosenfield RL. Etiology and pathophysiology of polycystic ovary syndrome in adolescents. www.uptodate.com Wolters Kluwer
• 5 Waldman IN, Legro RS. Polycystic ovary syndrome. In The Ovary. Amsterdam: Elsevier; 2019: 415-435
• 6 Papalou O, MVictor V, Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Curr Pharm Design 2016; 22: 2709-2722
• 7 Aquino CI, Nori SL. Complementary therapy in polycystic ovary syndrome. Transl Med@ UniSa 2014; 9: 56
• 8 Wrobel JK, Power R, Toborek M. Biological activity of selenium: Revisited. IUBMB Life 2016; 68: 97-105
• 9 Kipp AP. Selenium and selenoproteins in redox signaling. Free Radical Biol Med 2017; 108: S1-S3
• 10 Duntas LH, Hubalewska-Dydejczyk A. Selenium and Inflammation—Potential Use and Future Perspectives. US Endocrinol 2015; 11: 97-102
• 11 Papalou O, Diamanti-Kandarakis E. The role of stress in PCOS. Exp Rev Endocrinol Metab 2017; 12: 87-95
• 12 Shabani A, Noshadian M, Jamilian M. et al. The effects of a novel combination of selenium and probiotic on weight loss, glycemic control and markers of cardio-metabolic risk in women with polycystic ovary syndrome. J Funct Foods 2018; 46: 329-334
• 13 Coskun A, Arikan T, Kilinc M. et al. Plasma selenium levels in Turkish women with polycystic ovary syndrome. Eur J Obstetr Gynecol Reprod Biol 2013; 168: 183-186
• 14 Montes-Nieto R, Insenser M, Martínez-García MÁ. et al. A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes. J Clin Endocrinol Metab 2013; 98: E576-E585
• 15 Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Dysregulation of cytochrome P450 17α-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1720-1727
• 16 Modarres SZ, Heidar Z, Foroozanfard F. et al. The Effects of selenium supplementation on gene expression related to insulin and lipid in infertile polycystic ovary syndrome women candidate for in vitro fertilization: A randomized, double-blind, placebo-controlled trial. Biol Trace Element Res 2018; 183: 218-225
• 17 Zagrodzki P, Krzyczkowska-Sendrakowska M, Nicol F. et al. Selenium status parameters in patients with polycystic ovary syndrome. J Trace Element Med Biol 2017; 44: 241-246
• 18 Kanafchian M, Mahjoub S, Esmaeilzadeh S. et al. Status of serum selenium and zinc in patients with the polycystic ovary syndrome with and without insulin resistance. Middle East Fertil Soc J 2018; 23: 241-245
• 19 Hosseinzadeh FM, Hosseinzadeh-Attar MJ, Yekaninejad MS. et al. Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome: A randomized, double blinded, placebo controlled clinical trial. J Trace Element Med Biol 2016; 34: 56-61
• 20 Jamilian M, Razavi M, Fakhrie Kashan Z. et al. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol 2015; 82: 885-891
• 21 Köse SA, Nazıroğlu M. Selenium reduces oxidative stress and calcium entry through TRPV1 channels in the neutrophils of patients with polycystic ovary syndrome. Biol Trace Element Res 2014; 158: 136-142
• 22 Razavi M, Jamilian M, Kashan ZF. et al. Selenium supplementation and the effects on reproductive outcomes, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome. Horm Metab Res 2016; 48: 185-190
• 23 Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897-1899
• 24 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 25 Stranges S, Marshall JR, Natarajan R. et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann Intern Med 2007; 147: 217-223
• 26 Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661-665
• 27 Uno K, Katagiri H, Yamada T. et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 2006; 312: 1656-1659
• 28 Liu M-L, Ylitalo K, Salonen R. et al. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscl Thromb Vascul Biol 2004; 24: 1492-1497
• 29 Puttabyatappa M, VandeVoort CA, Chaffin CL. hCG-induced down-regulation of PPARγ and liver X receptors promotes periovulatory progesterone synthesis by macaque granulosa cells. Endocrinology 2010; 151: 5865-5872
• 30 Steinbrenner H. Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism. Free Radical Biol Med 2013; 65: 1538-1547
• 31 Apridonidze T, Essah PA, Iuorno MJ. et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-1935
• 32 Poretsky L. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582
• 33 Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Polycystic Ovary Syndrome. Delft: Karger Publishers; 2013: 22-27
• 34 Jakimiuk AJ, Weitsman SR, Navab A. et al. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001; 86: 1318-1323
• 35 Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Polycystic Ovary Syndrome.l Delft: Karger Publishers 2013; 51-63
• 36 González F, Rote NS, Minium J. et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 336-340
• 37 Mohamadin AM, Habib FA, Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome. Pathophysiology 2010; 17: 189-196
• 38 Fenkci IV, Serteser M, Fenkci S. et al. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007; 52: 879-883
• 39 Pawelczak M, Rosenthal J, Milla S. et al. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2014; 27: 356-359
• 40 Scicchitano P, Dentamaro I, Carbonara R. et al. Cardiovascular risk in women with PCOS. Int J Endocrinol Metab 2012; 10: 611-618
• 41 Steinbrenner H, Steinbrenner H, Bilgic E. et al. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radical Res 2006; 40: 936-943
• 42 Zou X-F, Ji Y-T, Gao G. et al. A novel selenium-and copper-containing peptide with both superoxide dismutase and glutathione peroxidase activities. J Microbiol Biotechnol 2010; 20: 88-93
• 43 Zeng J, Zhou J, Huang K. Effect of selenium on pancreatic proinflammatory cytokines in streptozotocin-induced diabetic mice. J Nutr Biochem 2009; 20: 530-536
• 44 González F, Rote NS, Minium J. et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 336-340
• 45 Wang Y, Lin M, Gao X. et al. High dietary selenium intake is associated with less insulin resistance in the Newfoundland population. PloS One 2017; 12: e0174149
• 46 Hesse-Bahr K, Dreher I, Kohrle J. The influence of the cytokines Il-1beta and INFgamma on the expression of selenoproteins in the human hepatocarcinoma cell line HepG2. Biofactors 2000; 11: 83-85
• 47 Nichol C, Herdman J, Sattar N. et al. Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: Further evidence for a negative acute phase response?. Clin Chem 1998; 44: 1764-1766
• 48 Renko K, Hofmann PJ, Stoedter M. et al. Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice. FASEB J 2009; 23: 1758-1765
• 49 Li YB, Han JY, Jiang W. et al. Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells. Mol Biol Rep 2011; 38: 2301-2306
• 50 Stapleton SR. Selenium: an insulin-mimetic. Cell Mol Life Sci 2000; 57: 1874-1879
• 51 Hei YJ, Farahbakhshian S, Chen X. et al. Stimulation of MAP kinase and S6 kinase by vanadium and selenium in rat adipocytes. Mol Cell Biochem 1998; 178: 367-375
• 52 Victor VM, Rocha M, Banuls C. et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2011; 96: 3115-3122
• 53 Victor VM, Rocha M, Banuls C. et al. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2009; 94: 3505-3512
• 54 Ayub K, Hallett MB. Ca2+influx shutdown during neutrophil apoptosis: Importance and possible mechanism. Immunology 2004; 111: 8-12
• 55 Naziroglu M, Sahin M, Cig B. et al. Hypericum perforatum modulates apoptosis and calcium mobilization through voltage-gated and TRPM2 calcium channels in neutrophil of patients with Behcet's disease. J Memb Biol 2014; 247: 253-262
• 56 Kayan M, Naziroglu M, Ovey IS. et al. Non-ionic contrast media induces oxidative stress and apoptosis through Ca(2)(+) influx in human neutrophils. J Memb Biol 2012; 245: 833-840
• 57 Uno K, Katagiri H, Yamada T. et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 2006; 312: 1656-1659
• 58 Puttabyatappa M, Vandevoort CA, Chaffin CL. hCG-induced down-regulation of PPARgamma and liver X receptors promotes periovulatory progesterone synthesis by macaque granulosa cells. Endocrinology 2010; 151: 5865-5872
• 59 Kim JE, Choi SI, Lee HR. et al. Selenium significantly inhibits adipocyte hypertrophy and abdominal fat accumulation in OLETF rats via induction of fatty acid beta-oxidation. Biol Trace Elem Res 2012; 150: 360-370
• 60 Kaur HD, Bansal MP. Studies on HDL associated enzymes under experimental hypercholesterolemia: Possible modulation on selenium supplementation. Lipids Health Disease 2009; 8: 55
• 61 Misu H, Takamura T, Takayama H. et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010; 12: 483-495
• 62 Yang SJ, Hwang SY, Choi HY. et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 2011; 96: E1325-E1329
• 63 Roman M, Lapolla A, Jitaru P. et al. Plasma selenoproteins concentrations in type 2 diabetes mellitus – a pilot study. Transl Res 2010; 156: 242-250
• 64 Hurst R, Armah CN, Dainty JR. et al. Establishing optimal selenium status: Results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2010; 91: 923-931
• 65 Xia Y, Hill KE, Li P. et al. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: A placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr 2010; 92: 525-531
• 66 Suresh S, Vijayakumar T. Correlations of insulin resistance and serum testosterone levels with LH:FSH ratio and oxidative stress in women with functional ovarian hyperandrogenism. Indian J Clin Biochem 2015; 30: 345-350
• 67 Hauner H, Ditschuneit HH, Pal SB. et al. Fat distribution, endocrine and metabolic profile in obese women with and without hirsutism. Metabolism 1988; 37: 281-286
• 68 Munzker J, Hofer D, Trummer C. et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100: 653-660
• 69 Poretsky L, Cataldo NA, Rosenwaks Z. et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582
• 70 Pugeat M, Crave JC, Elmidani M. et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 1991; 40: 841-849
• 71 Rezvanfar MA, Rezvanfar MA, Ahmadi A. et al. Molecular mechanisms of a novel selenium-based complementary medicine which confers protection against hyperandrogenism-induced polycystic ovary. Theriogenology 2012; 78: 620-631
• 72 Teede HJ, Misso ML, Costello MF. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reprod 2018; 33: 1602-1618